Blood management strategies in congenital Glanzmann thrombasthenia at a hematology referral center

다국어 초록 (Multilingual Abstract)

Background Glanzmann thrombasthenia is associated with abnormalities in the glycoprotein IIb/IIIa receptor. This study, conducted at Ampang Hospital, Malaysia, aimed to assess outcomes of blood management strategies for Glanzmann thrombasthenia.
Methods Ten patients with Glanzmann thrombasthenia aged 9 years (2009‒2018) were examined.
Data on clinical characteristics, transfusion practices, and patient blood management were obtained from medical records. Patient blood management methods included parenteral iron, erythropoietin, hormonal pills, intrauterine progesterone contraceptive devices, tranexamic acid, and recombinant factor VIIa. Primary outcomes were hemoglobin levels and the proportion of patients who received blood transfusion. Secondary outcomes were morbidity and mortality.
Results The median age at diagnosis was 8.2 years (range, 1‒15 yr). The female-to-male ratio was 9:1. Eight patients had type 2 disease (5‒20% of normal GPIIb/IIIa), and two patients had type 1 disease (normal GPIIb/IIIa ＜5%). All patients had iron deficiency. All female patients presented with significant menorrhagia. Other bleeding symptoms included epistaxis, spontaneous skin bruising, hemoptysis, gingival bleeding, knee hemarthrosis, and pelvic hematoma. No patient experienced life-threatening bleeding. Our patients had a mean hemoglobin level of 5.6 g/dL at diagnosis. All patients were optimized using non-transfusion methods as described above. Our patient had a current mean hemoglobin level of 11 g/dL. Approximately 70% (7/10) of patients did not experience receiving blood transfusions in the last 5 years. No patient experienced non-transfusion-related morbidities such as sepsis, thromboembolism, or cardiorespiratory events.
Conclusion High cost, transfusion-related adverse events, and immunomodulation could be effectively prevented by avoiding unnecessary blood transfusions.

참고문헌 (Reference)

1 Law RHP, "X ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors" 1 : 766-771, 2017

2 Isbister J, "Why should health professionals be concerned about blood management and blood conservation? Updates in Blood Conservation and Transfusion Alternatives" 2 : 3-7, 2005

3 Jobe SM, "Transfusion medicine and hemostasis: clinical and laboratory aspects" Elsevier 467-468, 2009

4 Allen GA, "The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation" 11 (11): S3-S7, 2000

5 Franchini M, "Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery : a meta-analysis of randomised controlled trials" 16 : 36-43, 2018

6 Chitlur M, "Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders" 10 : 95-99, 2017

7 Toogeh G, "Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran" 77 : 198-199, 2004

8 Lindley CM, "Pharmacokinetics and pharmacodynamics of recombinant factor VIIa" 55 : 638-648, 1994

9 Matteson KA, "Nonsurgical management of heavy menstrual bleeding : a systematic review" 121 : 632-643, 2013

10 Hendrickson JE, "Noninfectious serious hazards of transfusion" 108 : 759-769, 2009

11 Hillard PA, "Menstrual suppression : current perspectives" 6 : 631-637, 2014

12 Khalafallah AA, "Intravenous ferric carboxymaltose versus standard care in the management of postoperative care anemia : a prospective, open-label, randomised controlled trial" 3 : e415-e425, 2016

13 Miller JL, "Glycoprotein analysis for the diagnostic evaluation of platelet disorders" 35 : 224-232, 2009

14 Pittman MA Jr, "Glanzmann’s thrombopathy : an autosomal recessive trait in one family" 247 : 293-303, 1964

15 George JN, "Glanzmann’s thrombasthenia : the spectrum of clinical disease" 75 : 1383-1395, 1990

16 Solh T, "Glanzmann’s thrombasthenia : pathogenesis, diagnosis, and current and emerging treatment options" 6 : 219-227, 2015

17 Nurden AT, "Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models" 118 : 5996-6005, 2011

18 Nurden AT, "Expanding the mutation spectrum affecting II3 integrin in Glanzmann thrombasthenia : screening of the ITGA2B and ITGB3 genes in a large international cohort" 36 : 548-561, 2015

19 Reichert N, "Clinical and genetic aspects of Glanzmann’s thrombasthenia in Israel : report of 22 cases" 34 : 806-820, 1975

20 Farsinejad A, "Classification of Iranian patients with Glanzmann’s thrombasthenia using a flow cytometric method" 22 : 321-327, 2011

21 Bevan JA, "Bleeding disorders : a common cause of menorrhagia in adolescents" 138 : 856-861, 2001

22 Spahn DR, "Alternatives to blood transfusion" 381 : 1855-1865, 2013

23 Tholouli E, "Acquired Glanzmann’s thrombasthenia without thrombocytopenia : a severe acquired autoimmune bleeding disorder" 127 : 209-213, 2004